Core Viewpoint - Shanghai Pharmaceuticals has received approval from the National Medical Products Administration for the change of marketing authorization holder for Amisulpride Orally Disintegrating Tablets to its subsidiary, Shanghai Shiyou Zhongxi Pharmaceutical Co., Ltd [1] Group 1: Company Developments - The marketing authorization holder for Amisulpride Orally Disintegrating Tablets has been officially changed to Shanghai Shiyou Zhongxi Pharmaceutical Co., Ltd [1] - The company submitted the registration application for the change of marketing authorization holder to the National Medical Products Administration in September 2025, which has been accepted [1] - The company has invested approximately 31.5 million yuan in the development of this drug as of the date of the announcement [1] Group 2: Market Context - Amisulpride Orally Disintegrating Tablets is a modified formulation of Amisulpride, originally launched by Sanofi in France in 1986, used for the treatment of adult schizophrenia [1] - As of the announcement date, there are no other companies in China that have listed Amisulpride Orally Disintegrating Tablets [1] - According to the IQVIA database, the hospital procurement amount for Amisulpride oral formulations in 2024 is projected to be 168 million yuan [1]

Core Viewpoint - Shanghai Pharmaceuticals (02607.HK) announced that its subsidiary, Shanghai Shiyou Chinese-Western Medicine Co., Ltd. (referred to as "Shiyou"), has received the approval notice from the National Medical Products Administration for the change of the marketing authorization holder for Amisulpride Orally Disintegrating Tablets to Shanghai Shiyou [1] Group 1 - The approval notice includes notification numbers: 2025B04804 and 2025B04815 [1]

香港交易及結算所有限公司和香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產生或因依賴 該等內容而引致的任何損失承擔任何責任。 上 海 醫 藥 集 團 股 份 有 限 公 司 Shanghai Pharmaceuticals Holding Co., Ltd. * （於中華人民共和國註冊成立的股份有限公司） （股份代碼：02607） 海外監管公告 本公告乃根據香港聯合交易所有限公司證券上市規則第 13.10B 條而作出。 茲載列上海醫藥集團股份有限公司（「本公司」）在上海證券交易所網站(http://www.sse.com.cn) 刊登的《上海醫藥集團股份有限公司關於子公司成為氨磺必利口崩片上市許可持有人的公 告》僅供參閱。 承董事會命 上海醫藥集團股份有限公司 楊秋華 董事長 证券代码：601607 证券简称：上海医药 编号：临 2025-093 上海医药集团股份有限公司 关于子公司成为氨磺必利口崩片上市许可持有人的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确 ...

Core Insights - The pharmaceutical commercial sector experienced a decline of 1.0% on October 24, with Jianfa Zhixin leading the drop [1] - The Shanghai Composite Index closed at 3950.31, up 0.71%, while the Shenzhen Component Index closed at 13289.18, up 2.02% [1] Market Performance - The following companies showed varied performance in the pharmaceutical commercial sector: - Huaren Health (301408) closed at 13.17, up 0.46% with a trading volume of 44,500 shares and a turnover of 58.44 million yuan [1] - Runda Medical (603108) closed at 14.76, up 0.20% with a trading volume of 64,400 shares and a turnover of 95.39 million yuan [1] - Jianfa Zhixin (301584) led the decline, closing at 35.66, down 4.14% with a trading volume of 341,300 shares and a turnover of 1.289 billion yuan [2] Capital Flow - The pharmaceutical commercial sector saw a net outflow of 259 million yuan from institutional investors, while retail investors contributed a net inflow of 248 million yuan [2] - The following companies had notable capital flows: - Shanghai Pharmaceutical (601607) had a net inflow of 6.9169 million yuan from institutional investors [3] - Baiyang Pharmaceutical (301015) experienced a net inflow of 6.5687 million yuan from institutional investors [3] - Runda Medical (603108) had a net inflow of 3.8868 million yuan from retail investors [3]

证券代码：601607 证券简称：上海医药 编号：临 2025-093 上海医药集团股份有限公司 关于子公司成为氨磺必利口崩片上市许可持有人的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 近日，上海医药集团股份有限公司（以下简称"上海医药"或"公司"）下 属上海上药中西制药有限公司（以下简称"上药中西"）收到国家药品监督管理 局（以下简称"国家药监局"）颁发的《药品补充申请批准通知书》（通知书编 号：2025B04804、2025B04815），其同意将氨磺必利口崩片（以下简称"该药 品"）上市许可持有人变更为上海上药中西制药有限公司。 一、该药品的基本情况 药品名称：氨磺必利口崩片 二、该药品的相关信息 氨磺必利口崩片是赛诺菲（Sanofi）公司于 1986 年在法国上市的氨磺必利 片的改良剂型，用于治疗成人精神分裂症。2025 年 9 月，上药中西就该药品上 市许可持有人变更向国家药监局提出注册上市申请并获受理。截至本公告日，公 司针对该药品已投入约人民币 3,150 万元。 截至本公告日，中国境内氨磺必利口 ...

Core Viewpoint - Shanghai Pharmaceuticals (601607.SH) has received approval from the National Medical Products Administration to change the marketing authorization holder for Amisulpride Orally Disintegrating Tablets to its subsidiary, Shanghai Pharmaceuticals Zhongxi Pharmaceutical Co., Ltd. This move is expected to enhance the company's product line and market competitiveness [1]. Group 1 - The National Medical Products Administration issued a "Drug Supplement Application Approval Notice" allowing the change of marketing authorization holder for Amisulpride Orally Disintegrating Tablets [1]. - Amisulpride Orally Disintegrating Tablets is an improved formulation of Amisulpride, originally launched by Sanofi in France in 1986, used for treating adult schizophrenia [1]. - The change in marketing authorization holder to Shanghai Pharmaceuticals Zhongxi is anticipated to enrich the company's product offerings and strengthen its competitive position in the market [1].

Core Viewpoint - Shanghai Pharmaceuticals (601607.SH) announced that its subsidiary, Shanghai Shiyou Zhongxi Pharmaceutical Co., Ltd. (referred to as "Shiyou Zhongxi"), has received a notification from the National Medical Products Administration (NMPA) approving the change of the marketing authorization holder for Amisulpride Orally Disintegrating Tablets to Shiyou Zhongxi [1] Group 1 - The NMPA has granted approval for the change of marketing authorization holder for Amisulpride Orally Disintegrating Tablets [1] - Amisulpride Orally Disintegrating Tablets are an improved formulation of Amisulpride Tablets, which were launched by Sanofi in France in 1986, and are used for the treatment of adult schizophrenia [1] - Shiyou Zhongxi submitted the registration application for the change of marketing authorization holder to the NMPA in September 2025, which has been accepted [1]

Core Viewpoint - Shanghai Pharmaceuticals (601607.SH) announced that its subsidiary, Shanghai Shiyou Zhongxi Pharmaceutical Co., Ltd., received a notification from the National Medical Products Administration approving the change of the marketing authorization holder for Amisulpride Orally Disintegrating Tablets to Shanghai Shiyou Zhongxi Pharmaceutical Co., Ltd. [1] Group 1 - The Amisulpride Orally Disintegrating Tablets are an improved formulation of Amisulpride Tablets, which were originally launched by Sanofi in France in 1986 for the treatment of adult schizophrenia [1] - The application for the change of marketing authorization holder was submitted to the National Medical Products Administration in September 2025 and has been accepted [1]

Core Viewpoint - The event organized by Shanghai Pharmaceuticals Jiangsu aims to promote health weight management and establish a new standard for healthy workplaces in response to the national call for a "Weight Management Year" [1] Group 1: Event Overview - The health weight management initiative took place in Wuxi, Jiangsu, combining offline interactions and lectures to educate employees on weight management [2] - Hundreds of employees actively participated in the event, creating a lively atmosphere [3] Group 2: Expert Insights - Renowned experts provided in-depth lectures on the dangers of obesity and scientific weight management strategies, emphasizing the importance of dietary structure optimization rather than merely reducing intake [4] - The obesity prevalence among adults in China has reached 16.4%, with overweight and obese individuals facing over three times the risk of cardiovascular diseases [4] Group 3: Personalized Health Management - A dedicated team of weight management professionals offered one-on-one health assessments and personalized nutrition plans, addressing common weight loss challenges [5] - Employees expressed appreciation for the event, recognizing the potential health risks associated with obesity and the need for a scientific approach to weight management [5] Group 4: Corporate Responsibility and Future Actions - The initiative reflects the company's commitment to integrating health management into workplace culture, transitioning employees from passive health to proactive management [6] - The program is part of a broader effort to contribute to the Healthy China 2030 strategy, with plans to extend similar activities to more enterprises nationwide [6]

Core Insights - The pharmaceutical commercial sector saw an increase of 0.83% on October 22, with Jianfa Zhixin leading the gains [1] - The Shanghai Composite Index closed at 3913.76, down 0.07%, while the Shenzhen Component Index closed at 12996.61, down 0.62% [1] Stock Performance - Jianfa Zhixin (301584) closed at 31.00, up 7.19% with a trading volume of 238,100 shares and a transaction value of 734 million [1] - Guoyao Shares (600511) closed at 29.89, up 3.75% with a trading volume of 180,500 shares and a transaction value of 539 million [1] - Zhejiang Nongyuan (000705) closed at 9.81, up 3.05% with a trading volume of 117,170 shares and a transaction value of 168 million [1] - Other notable stocks include Jiashitang (002462) up 1.51%, Daclin (603233) up 1.34%, and Guofa Shares (600538) up 1.20% [1] Capital Flow - The pharmaceutical commercial sector experienced a net outflow of 98.42 million from institutional investors and 51.45 million from retail investors, while individual investors saw a net inflow of 150 million [2] - The capital flow for key stocks shows varying trends, with Shanghai Pharmaceuticals (601607) seeing a net inflow of 31.94 million from institutional investors [3] - Jianfa Zhixin (301584) had a net inflow of 18.64 million from institutional investors but a net outflow of 2.07 million from retail investors [3]